I agree with imtesty. DM indicated he was going to take a much deeper dive into the data and spill a lot more beans. There are several secondary endpoints that were not covered yesterday. There were a few subgroup analyses for the primary outcome not covered yesterday. And most importantly there is the CKD sub-study data (eGFR change, etc) in patients with baseline eGFR<60 that was not covered yesterday. I think DM said he plans to reveal everything except cognition, which needs to stay under embargo until CTAD. I think a lot of stuff that the clinical team wanted to save until March 2020.....DM will be presenting tomorrow morning instead. I am most looking forward to hearing more about the observation of the 50% RRR for 3-point MACE in those patients w/ baseline eGFR<60 and the 40% RRR for 3-point MACE in those patients with baseline LDL-C below the median.

BDAZ